FDA-cleared profile

OrthoGrid Hip AI® 4.0

OrthoGrid Systems, Inc.

OrthoGrid Hip AI 4.0 analyzes two-dimensional C-arm fluoroscopic images to assist positioning of hip-replacement components during direct-anterior total hip arthroplasty.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
OrthoGrid Hip AI 4.0 analyzes two-dimensional C-arm fluoroscopic images to assist positioning of hip-replacement components during direct-anterior total hip arthroplasty.
FDA source Exact FDA submission Checked 2026-09-04
Intended users
Qualified physicians and healthcare professionals performing or supporting the labeled diagnostic or interventional procedure.
FDA source Exact FDA submission Checked 2026-09-04
Care setting and population
Interventional, catheterization, operating-room, emergency, or other professional procedural settings within the labeled use.
FDA source Exact FDA submission Checked 2026-09-04
Workflow role
OrthoGrid Hip AI 4.0 analyzes two-dimensional C-arm fluoroscopic images to assist positioning of hip-replacement components during direct-anterior total hip arthroplasty.
FDA source Exact FDA submission Checked 2026-09-04
Required input
Digital radiographic, fluoroscopic, or angiographic images acquired by the supported system.
FDA source Exact FDA submission Checked 2026-09-04
Output and human action
Displayed, processed, enhanced, measured, or guided fluoroscopic information described in the exact FDA labeling.
FDA source Exact FDA submission Checked 2026-09-04
Limitations
It is an intraoperative aid rather than primary image interpretation; use is limited to the labeled direct-anterior hip-replacement workflow and clinician decisions.
FDA source Exact FDA submission Checked 2026-09-04

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K260077
FDA source Exact FDA submission Checked 2026-08-31
Modality
Fluoroscopy/Angiography
FDA source Exact FDA submission Checked 2026-09-04
Anatomy
Hip
FDA source Exact FDA submission Checked 2026-09-04
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2026-05-29
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Operates on two-dimensional C-arm fluoroscopic images with the labeled case-data transfer workflow; local interface and round-trip behavior require acceptance.
FDA source Exact FDA submission Checked 2026-09-04
Deployment and data flow
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-04

Deployment details for the exact cleared configuration are not established in the public FDA decision material.

Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

Security controls, hosting boundaries, audit behavior, identity management, and incident commitments for the exact configuration are not established in the public FDA decision material.

Training and support
Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
FDA source Exact FDA submission Checked 2026-09-04
Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-04

Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K260077 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Operates on two-dimensional C-arm fluoroscopic images with the labeled case-data transfer workflow; local interface and round-trip behavior require acceptance.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. It is an intraoperative aid rather than primary image interpretation; use is limited to the labeled direct-anterior hip-replacement workflow and clinician decisions.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the evidence set; productivity or value claims require local evidence.

Lifecycle monitoring

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.

exact submission · checked 2026-09-04

Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
The exact FDA decision material describes the labeled intended use and submission-level verification for this release. It does not establish a product-wide clinical sensitivity or specificity claim or independent clinical outcome evidence.
FDA source Exact FDA submission Checked 2026-09-04
Reported sensitivity
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No exact-product, version-specific sensitivity endpoint was established for this submission in the evidence set.

Reported specificity
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No exact-product, version-specific specificity endpoint was established for this submission in the evidence set.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K260077 FDA evidence package for OrthoGrid Hip AI® 4.0

FDA submission-level decision material with device, software, performance, safety, and/or usability verification as applicable; not independent clinical validation. · Population and workflow are limited to the exact FDA labeling summarized for this submission.

exact submission · Tested version: Exact FDA submission release; version not separately stated in the public decision material · Sponsor or vendor study

K260077

Evidence submitted for the exact FDA decision is not independent clinical validation. Local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No public list price for the exact cleared configuration was found in the evidence set. Obtain a written quote covering license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, downtime, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, dental, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
Public source Not applicable Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Reviewed CMS material is not a product-specific price or coverage determination; do not infer reimbursement from FDA clearance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K260077 by native exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source Exact FDA submission Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
9Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

This submission was added after the prior exact-submission extraction and remains queued for source review. Exact FDA decision material was reviewed for identity and labeled use. Optional literature, trial, and recall candidates were not promoted without exact product or version applicability; commercial, security, and performance claims remain unknown where not established. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-04.

Alternatives

Related tools to compare

FDA-cleared K253551

VELYS™ Hip Navigation

Depuy Ireland UC

VELYS Hip Navigation analyzes intraoperative X-ray or fluoroscopy for total hip arthroplasty with surgeon-confirmed landmark suggestions and measurements of cup orientation, leg...

Modality
Fluoroscopy/Angiography
Anatomy
Hip
Decision
2026-03-06
FDA-cleared K252503

Intelligent NR

Canon, Inc.

Canon Intelligent NR is a noise-reduction function for fluoroscopic images acquired on compatible Canon radiography and fluoroscopy systems.

Modality
Fluoroscopy/Angiography
Anatomy
Whole body; diagnostic and interventional anatomy
Decision
2026-04-30
FDA-cleared K253269

OEC One CFD

Ge Hualun Medical Systems Co., Ltd.

OEC One CFD provides fluoroscopic and digital-spot images for adult and pediatric diagnostic, interventional, surgical, orthopedic, gastrointestinal, urologic, neurologic,...

Modality
Fluoroscopy/Angiography
Anatomy
Orthopedic, gastrointestinal, endoscopic, urologic, neurologic, vascular, critical-care, and emergency anatomy
Decision
2025-11-26
FDA-cleared K243446

3DXR

GE Medical Systems SCS

3DXR reconstructs cone-beam CT from interventional X-ray acquisitions and uses CleaRecon DL to reduce streak artifacts for display in the advanced workstation workflow.

Modality
Fluoroscopy/Angiography
Anatomy
Multi-region
Decision
2025-02-25